Campaign US12h
‘Check before you inject’: Novo bites back at Hims & Hers Super Bowl ad
Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
Hims & Hers Super Bowl Ad Controversy - Here's The Latest
Hims & Hers faced backlash over its Super Bowl ad touting its compound weight loss drug while slamming pharmaceutical giants ...
MarketBeat on MSN14h
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 ...
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...